Hyperfine (HYPR) Capital Expenditures Growth (5y) (2026)
Hyperfine (HYPR) Capital Expenditures Growth (5y) (2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.82 Bn | 176.53 Bn | 6.27 Bn |
| 2 | Stryker | 129.01 Bn | 126.13 Bn | 3.81 Bn |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.59 Bn | 67.14 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.68 Bn | 1.29 Bn |
| 6 | Dexcom | 28.35 Bn | 27.23 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.11 Bn | 25.82 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - |
| 9 | Koninklijke Philips | 24.28 Bn | 21.15 Bn | 2.07 Bn |
| 10 | Hyperfine | 94.44 Mn | 53.16 Mn | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.53% |